Harold Rosen, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editors: I am intrigued by the findings recently reported by Gallagher and Goldgar (1). They describe a significant increase in vertebral bone mineral density in patients with postmenopausal osteoporosis treated with 1,25(OH)2 vitamin D. However, although their data suggest the possible utility of 1,25(OH)2 vitamin D in the treatment of postmenopausal osteoporosis, most of their patients were substantially hypercalcuric by the end of the study. According to the authors' Table 2, the average urinary calcium in the treated patients was 6.4 mmol/d (256 mg/d). This means that more than 50% of their patients met conventional criteria for hypercalcuria
Rosen H. 1,25(OH)2 Vitamin D for Osteoporosis. Ann Intern Med. ;114:519–520. doi: 10.7326/0003-4819-114-6-519
Download citation file:
Published: Ann Intern Med. 1991;114(6):519-520.
Endocrine and Metabolism, Metabolic Bone Disorders.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use